Law360 Canada ( September 2, 2021, 5:34 AM EDT) -- Appeal by Alexion Pharmaceuticals from the dismissal of its application for judicial review of a decision of the Patented Medicine Prices Review Board finding that Alexion priced its drug, Soliris, excessively. Soliris was a breakthrough treatment for two rare and life-threatening blood-related disorders. The Board relied upon the fact that the list price of Soliris was higher than the price in one of the seven countries used for comparison purposes. This was the first time the Board ever imposed the requirement that the price of Soliris had to be lower than that of all seven comparator countries. Alexion submitted to the Board that the Board’s decision to require Soliris to be below the price in the seven comparator countries was contrary to s. 85 in that it exalted the factor of international prices under s. 85(1)(c) above all other factors and effectively read out of the section the factor of the consumer pricing index in s. 85(1)(d)....